Several studies have demonstrated the efficacy of oral bisphosphonates to prevent hormonal therapy induced bone loss particularly with aromatase inhibitors in breast cancer as summarized by Rizzoli et al. in a systematic review [72] and the meta-analysis of Su [73]. This evidence concerns the gene CYP19A1 and breast carcinoma.